Gandeeva Therapeutics

Gandeeva Therapeutics is a precision biotechnology company based in Burnaby, British Columbia, Canada, founded in 2021.

The company focuses on advancing drug discovery by targeting transient and challenging protein interactions. With a successful $40 million Series A funding round in January 2022, Gandeeva aims to develop innovative molecular therapeutics, including molecular glues and allosteric inhibitors, primarily for oncology applications. Gandeeva utilizes a proprietary platform that integrates artificial intelligence, machine learning, structural biology, and cryogenic electron microscopy (cryo-EM) to enhance drug discovery. Their technology includes three main modules: SPOTLIGHTTM for target prediction, HYPERFOCUSTM for atomic-resolution imaging, and CRYO-CADDTM for lead optimization. The company is actively developing a preclinical oncology pipeline with four drug candidates focused on modulating key protein-protein interactions that drive cancer progression. Gandeeva collaborates with major pharmaceutical firms, including Moderna and Amgen Ventures, to leverage its technology in therapeutic development.